Low-grade ESS is considered a hormone-dependent malignancy, which means hormonal therapy with high-dose oral progestins, gonadotropin-releasing hormone analogs, and aromatase inhibitors may be effective. This evidence concerns the gene CYP19A1 and endometrioid stromal sarcoma.